Jewish World Review

JWR's Pundits
World Editorial
Cartoon Showcase

Mallard Fillmore

Michael Barone
Mona Charen
Linda Chavez
Greg Crosby
Larry Elder
Don Feder
Suzanne Fields
James Glassman
Paul Greenberg
Bob Greene
Betsy Hart
Nat Hentoff
David Horowitz
Marianne Jennings
Michael Kelly
Mort Kondracke
Ch. Krauthammer
Lawrence Kudlow
Dr. Laura
John Leo
David Limbaugh
Michelle Malkin
Jackie Mason
Chris Matthews
Michael Medved
MUGGER
Kathleen Parker
Wes Pruden
Sam Schulman
Amity Shlaes
Roger Simon
Tony Snow
Thomas Sowell
Cal Thomas
Jonathan S. Tobin
Ben Wattenberg
George Will
Bruce Williams
Walter Williams
Mort Zuckerman

Consumer Reports


As Martha destructs, credibility of cancer drug at center of controversy soars

http://www.jewishworldreview.com | (KRT) The ImClone scandal may have ruined company chief Sam Waksal and damaged stockholder Martha Stewart, but the intriguing cancer drug at the root of it all, Erbitux, is emerging with its reputation intact.

The drug, whose initial government rejection led to securities-fraud charges against Waksal and Stewart, has shown promising results against colon cancer in its most recent study.

Erbitux is one of a handful of new drugs changing the direction of cancer treatment, designed to attack malignant cells without harming normal cells. Its reemergence may eventually eclipse the tawdry news that has surrounded its maker.

"This case illustrates the hopes and dreams and frustrations with the development of new treatments for cancer," said Louis Weiner, chairman of medical oncology at Fox Chase Cancer Center in Philadelphia.

"When you strip away all the sleaziness," Weiner said, "what has been learned about colon cancer is that in people whose cancers are no longer responding to chemotherapy, the addition of Erbitux will cause significant clinical improvement in 10 percent to 15 percent of cases." Combining Erbitux with more chemotherapy produces improvement in more than 20 percent of cases.

The drug has yet to be tested against people whose disease is less advanced and who therefore stand a better chance of recovery.

Donate to JWR

Colon cancer kills about 53,000 Americans every year, second only to lung cancer.

Erbitux and other "targeted" therapies aim to kill cancer cells while sparing healthy ones. They tend to have much less severe side effects.

"There's been a great interest in the past decade in identifying features of cancer cells that distinguish them from normal tissue," said Neal J. Meropol, director of the gastrointestinal-cancer program at Fox Chase.

The idea that was to become Erbitux emerged around 1980 in the mind of John Mendelsohn, who was doing cancer research at the University of California, San Diego. At the time, a number of cancer researchers were experimenting with the use of antibodies, proteins that the body's immune system makes to fight disease. But most researchers were looking at antibodies as a way to prompt a patient's immune system to kill cancer cells.

___

Mendelsohn took a different tack. He was trying to find ways that cancer cells differed from healthy ones - characteristics that could be exploited or targeted with antibody-based drugs.

Mendelsohn, along with colleague Gordon Sato, was interested in the various signals that prompt malignant cells to grow out of control. He and others found that the cancers depend on a substance called epidermal growth factor, or EGF.

A molecule of EGF is like the ignition key to a car, said Mendelsohn, who is now president of M.D. Anderson Cancer Center in Houston. That key fits into a lock - the EGF receptor - which sits on the surface of cells, he said.

Once the keys go into the locks, "the cells get a signal to proliferate," Mendelsohn said.

___

Ordinary cells also depend on EGF and EGF receptors, especially cells in the skin, but cancer cells have 1,000 times the normal number of EGF receptors, he said. That is one reason cancers tend to grow and spread.

Mendelsohn reasoned that if he could interfere with this lock-and-key system, he could stop cancers from growing. "How do you stop a key from getting into a lock?" he asks. "You put chewing gum in the lock."

The chewing gum he created was the antibody that was to become Erbitux.

Once the key gets into the lock, a number of other steps have to take place to signal the cell to divide. Other drugs interfere with the process at various points. Mendelsohn invented one such drug, called Iressa, which is now approved for treatment of lung cancer.

Mendelsohn started testing Erbitux against cancer cells in a test tube and tumors implanted in mice. It seemed to work, but so do many other drugs that eventually fail.

The Food and Drug Administration reports that only 20 percent to 25 percent of cancer drugs that look promising in the lab end up working well in real patients.

That is because samples of cancer that scientists study in test tubes or implant in mice are simpler than real cancerous tumors, with more uniform properties, Fox Chase's Meropol said. Real cancers tend to evolve various strategies for surviving and evading drugs.

When it came time to test Erbitux in people, ImClone Systems Inc. started with a group who had advanced colon cancer and who were not responding to the standard chemotherapy drug, called irinotecan.

Those people were given a combination of Erbitux and irinotecan. ImClone said that about 20 percent of them saw their tumors shrink.

Although the results suggested the drug could help many people with cancer, the FDA rejected ImClone's application for approval.

The FDA questioned not the drug itself but the way ImClone set up the trial.

When ImClone's CEO learned the drug would not be approved without further testing, he unloaded stock in his own company and urged his family to do the same. The government says Martha Stewart acted on a tip from her stockbroker and sold her 3,928 shares, too, avoiding losses of more than $45,000.

Waksal pleaded guilty to insider-trading charges and last month was sentenced to seven years in prison. Stewart has pleaded not guilty to charges that could mean jail time and stiff fines.

And yet, the drug was far from dead in scientific circles.

Two other targeted therapies have recently come on the market. One, Gleevec, has led to some dramatic recoveries for people with a certain type of leukemia known as CML. Another drug, Herceptin, seems to work well for certain cases of breast cancer. Like Erbitux, both of these drugs work by interfering with the way cells receive the signal to divide.

Women with breast cancer can now get a test that predicts how well they are likely to respond to Herceptin. Only 20 percent are candidates and even then, the drug does not always work. Herceptin saves lives, but it is far from a guaranteed cure.

Scientists say Erbitux will also work extremely well on about 10 percent of colon-cancer cases - but they do not yet have a test that predicts who is in that 10 percent.

"One hundred percent of appropriately selected people will respond," said Fox Chase's Weiner. "How do we find out who they are?"

Soon after the 2001 scandal broke a German company, Merck (not related to the U.S.-based Merck & Co.), conducted a similar trial to ImClone's but used Erbitux alone, as well as in combination with existing chemotherapy, as the FDA had suggested.

It did not cure anyone of advanced cancer, but in about 23 percent of the patients, the combination shrank their tumors and made the patients feel better. Erbitux alone shrank tumors for 11 percent of patients.

Scientists announced these results last month at a meeting of the American Society of Clinical Oncology.

It's not unusual for a new drug to create such a roller-coaster ride, Weiner said. "There have been instances of enormous hope, even hype, for these agents, followed by the puncturing of the balloon when they don't yield the results everyone had hoped for," he said. Erbitux is not a cure for cancer. "But in the end, you're ahead of where you started."

"My fervent hope is that FDA won't hold a grudge against ImClone and place unnecessary obstacles for what looks like a valuable addition to our treatment arsenal," he said.

Appreciate this type of reporting? Why not sign-up for the daily JWR update. It's free. Just click here.


Comment by clicking here.

Up

© 2003, The Philadelphia Inquirer Distributed by Knight Ridder/Tribune Information Services